| Enrollment | Baseline | Intervention period | Post-intervention | ||
---|---|---|---|---|---|---|
Week no: | -1 | 0 | 16 | 24 | 32 | 48 |
Informed consent | X | Â | Â | Â | Â | Â |
Screening | X | Â | Â | Â | Â | Â |
Sociodemographic and clinical characteristics | Â | X | Â | Â | Â | Â |
Neurodegeneration | ||||||
 Imaging |  | X | X |  | X | X |
 Blood sampling |  | X | X |  | X | X |
Patient functioning | ||||||
 • Mobility |  | X | X |  | X | X |
 • Dexterity |  | X | X |  | X | X |
 • Cognition |  | X | X |  | X | X |
 • Balance |  | X | X |  | X | X |
 • Disease |  | X | X |  | X | X |
 • Psychosocial |  | X | X |  | X | X |
 • Global perceived effect |  |  |  |  | X | X |
Cardiovascular risk factors | Â | X | X | Â | X | X |
Activity level during follow-up | Â | Â | Â | Â | Â | X |
Training Intensity | ||||||
 1RM |  | X | X | Xa | X | X |
 CPET |  | X | X | Xa | X | X |